(Q68938859)

English

Benefit-risk assessment of investigational drugs: current methodology, limitations, and alternative approaches

scientific article published on 01 November 1986

In more languages

edit

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

3547349

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3547349%20AND%20SRC:MED&resulttype=core&format=json

retrieved

28 September 2019

title

Benefit-risk assessment of investigational drugs: current methodology, limitations, and alternative approaches (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

3547349

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3547349%20AND%20SRC:MED&resulttype=core&format=json

retrieved

28 September 2019

author name string

D M Cocchetto

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

3547349

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3547349%20AND%20SRC:MED&resulttype=core&format=json

retrieved

28 September 2019

R V Nardi

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

3547349

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3547349%20AND%20SRC:MED&resulttype=core&format=json

retrieved

28 September 2019

publication date

1 November 1986

1 reference

stated in

Europe PubMed Central

PubMed publication ID

3547349

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3547349%20AND%20SRC:MED&resulttype=core&format=json

28 September 2019

1 reference

Europe PubMed Central

PubMed publication ID

3547349

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3547349%20AND%20SRC:MED&resulttype=core&format=json

retrieved

28 September 2019

volume

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

3547349

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3547349%20AND%20SRC:MED&resulttype=core&format=json

retrieved

28 September 2019

issue

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

3547349

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3547349%20AND%20SRC:MED&resulttype=core&format=json

retrieved

28 September 2019

page(s)

286-303

1 reference

stated in

Europe PubMed Central

PubMed publication ID

3547349

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3547349%20AND%20SRC:MED&resulttype=core&format=json

retrieved

28 September 2019

Identifiers

DOI

10.1002/J.1875-9114.1986.TB03491.X

1 reference

stated in

Europe PubMed Central

PubMed publication ID

3547349

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3547349%20AND%20SRC:MED&resulttype=core&format=json

retrieved

28 September 2019

PubMed publication ID

3547349

1 reference

stated in

Europe PubMed Central

PubMed publication ID

3547349

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3547349%20AND%20SRC:MED&resulttype=core&format=json

(Q68938859)

Benefit-risk assessment of investigational drugs: current methodology, limitations, and alternative approaches

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)